DI GIORGIO, CRISTINA
 Distribuzione geografica
Continente #
NA - Nord America 496
EU - Europa 280
AS - Asia 270
AF - Africa 5
SA - Sud America 1
Totale 1.052
Nazione #
US - Stati Uniti d'America 492
SG - Singapore 116
IT - Italia 104
IE - Irlanda 98
HK - Hong Kong 84
CN - Cina 35
DE - Germania 22
VN - Vietnam 21
FI - Finlandia 12
BE - Belgio 9
KR - Corea 8
UA - Ucraina 8
RU - Federazione Russa 7
AT - Austria 5
NL - Olanda 5
CA - Canada 4
CI - Costa d'Avorio 4
SE - Svezia 3
FR - Francia 2
AM - Armenia 1
AZ - Azerbaigian 1
BR - Brasile 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
EE - Estonia 1
GB - Regno Unito 1
GR - Grecia 1
ID - Indonesia 1
IR - Iran 1
LB - Libano 1
MA - Marocco 1
SA - Arabia Saudita 1
Totale 1.052
Città #
Chandler 133
Dublin 94
Singapore 92
Hong Kong 84
Boardman 41
Perugia 41
Santa Clara 35
San Mateo 22
Dong Ket 21
Ann Arbor 20
Medford 16
Princeton 16
Altamura 15
Lawrence 13
Wilmington 11
Brussels 9
Los Angeles 9
Munich 9
Helsinki 8
Seoul 8
Ashburn 7
Dallas 6
Des Moines 6
Redwood City 6
Beijing 5
Florence 5
Abidjan 4
Andover 4
Den Haag 4
Lappeenranta 4
Naples 4
Saint Petersburg 4
Toronto 4
Vienna 4
Bologna 3
Frankfurt am Main 3
Houston 3
Redmond 3
Seattle 3
Cambridge 2
Irpin 2
Menlo Park 2
Rome 2
San Diego 2
Athens 1
Baku 1
Boydton 1
Brno 1
Cascina 1
Caserta 1
Cava Dei Tirreni 1
Cormeilles-en-Parisis 1
Ercolano 1
Esslingen am Neckar 1
Fremont 1
Guiyang 1
Handan 1
Harbin 1
Huzhou 1
Jacksonville 1
Jinan 1
Liberty Lake 1
Lugano 1
Milan 1
Newark 1
Nocera Umbra 1
Norwalk 1
Philadelphia 1
Qingdao 1
Rabat 1
Radeberg 1
Riyadh 1
San Paolo di Civitate 1
São Paulo 1
Tallinn 1
Tenhult 1
Woodbridge 1
Yerevan 1
Zanjan 1
Zhengzhou 1
Totale 825
Nome #
Increasing the Astrophysical Reach of the Advanced Virgo Detector via the Application of Squeezed Vacuum States of Light 79
The aryl hydrocarbon receptor (AhR) mediates the counter-regulatory effects of pelargonidins in models of inflammation and metabolic dysfunctions 76
Identification of Cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1 66
GPBAR1 Activation by C6-Substituted Hyodeoxycholane Analogues Protect against Colitis 47
The Bile Acid Receptor GPBAR1 Modulates CCL2/CCR2 Signaling at the Liver Sinusoidal/Macrophage Interface and Reverses Acetaminophen-Induced Liver Toxicity 47
Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction 46
Bile Acids Activated Receptors in Inflammatory Bowel Disease 46
Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation 44
Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis 43
Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling 40
GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation 39
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH 37
Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease 37
Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis 37
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma 35
GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis 35
The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy 33
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma 32
Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders 32
Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury 29
Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling 28
Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease 25
Organoids as ex vivo culture system to investigate infection-host interaction in gastric pre-carcinogenesis 25
Discovery of a Novel Class of Dual GPBAR1 Agonists-RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders 22
Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis 17
Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease 17
The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer 16
Immunology of bile acids regulated receptors 13
BAR502/fibrate conjugates: synthesis, biological evaluation and metabolic profile 12
Current Landscape and Evolving Therapies for Primary Biliary Cholangitis 11
Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases 10
Modeling Inflammatory Bowel Disease by Intestinal Organoids 10
Design, Synthesis, and Pharmacological Evaluation of Dual FXR-LIFR Modulators for the Treatment of Liver Fibrosis 8
Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments 8
Analysis of Oral and Gut Microbiota Composition in Children with Dental Caries by NGS Approaches 5
Microbial-derived bile acid reverses inflammation in IBD via GPBAR1 agonism and RORγt inverse agonism 3
Totale 1.110
Categoria #
all - tutte 6.672
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.672


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202025 0 0 0 0 0 0 2 0 6 9 5 3
2020/202174 5 1 2 1 21 6 1 3 2 6 4 22
2021/2022125 2 20 0 3 1 1 11 21 3 15 16 32
2022/2023409 27 61 3 35 38 46 0 22 151 2 14 10
2023/2024204 10 15 4 6 12 1 47 28 19 9 33 20
2024/2025269 9 57 39 52 46 66 0 0 0 0 0 0
Totale 1.110